Development of vaccines against influenza A virus (H5N1)

Wen Chen Li, Yhu Chering Huang*

*此作品的通信作者

研究成果: 期刊稿件文獻綜述同行評審

1 引文 斯高帕斯(Scopus)

摘要

Three influenza pandemics took place during the 20th century, including the 1918 pandemic, which killed an estimated 50 million people. We are facing the threat of another pandemic, which may be caused by an A/H5N1 influenza virus. These viruses have expanded their territory from Asia to the Middle East, Africa and Europe and have caused more than 190 human deaths up to the present. Vaccines in response to this pandemic threat are currently under development. Reverse-genetics-based inactivated whole-virion vaccines and adjuvanted split-virion vaccines are undergoing clinical trials and are among possible candidates to be approved as H5N1 vaccines for human beings. Problems, including low immunogenicity in the generally naive human population, a lack of data on these vaccines in relation to immunocompromised patients, young children and the elderly and the currently limited global capacity to manufacture influenza vaccines, all need to be resolved. Several innovative approaches, such as the use of novel adjuvants, an antigen-sparing policy and the use of adenoviral-vector-based or DNA vaccines, are being used to develop more efficient vaccines. Every effort should be made to shorten the gap that remains and improve greatly influenza pandemic vaccine access.

原文英語
頁(從 - 到)294-304
頁數11
期刊Chang Gung Medical Journal
30
發行號4
出版狀態已出版 - 07 2007

指紋

深入研究「Development of vaccines against influenza A virus (H5N1)」主題。共同形成了獨特的指紋。

引用此